(CIDRAP News) Cost issues and the risk of viral resistance drew considerable attention today in an online presentation by federal health officials on their revised guidance regarding use of antiviral drugs in an influenza pandemic.
The Department of Health and Human Services (HHS) released two guidance documents this week, one on antiviral use in general and one on employer stockpiling of antivirals.